Oncoinvent ASA (OB: ONCIN)
Health Care · Pharmaceuticals · NO
Nkr71.20
-14.01% today · -30.4% 1Y
Oncoinvent ASA (OB: ONCIN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $52.71M and employs 42 people.
Over the last twelve months the share price has lost 30.4%, trading between 40.10 and 144.00.
Tweenvest scores Oncoinvent ASA across four factors: quality 42/100, value 51/100, growth 100/100. Its strongest factor is growth.
ONCIN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $52.71M
- Revenue (TTM)
- $2.45M
- P/E
- —
- EPS
- -57.11
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- Nkr144.00
- 52-week low
- Nkr40.10
- Avg volume (3M)
- —
- Shares outstanding
- 6.13M
- Employees
- 42
- Next earnings
- —
About Oncoinvent ASA
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
- ISIN
- NO0013711713
- Listed since
- Apr 7, 2017
- Exchange
- Oslo Bors
- Currency
- NOK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Wai Yuen Tong Medicine Holdings LimitedSEHK: 897 | $53.25M | HK$0.38 | +1.35% |
| Odonate, Inc.OTCPK: ODTC | $53.25M | $— | — |
| Ildong Holdings Co., Ltd.KOSE: A000230 | $53.04M | ₩6,190.00 | +4.21% |
| Anya Biopharm Inc.TPEX: 7776 | $52.87M | NT$34.30 | +3.78% |
| CKD Bio Corp.KOSE: A063160 | $52.10M | ₩12,790.00 | -0.23% |
| Enzychem Lifesciences CorporationKOSDAQ: A183490 | $51.50M | ₩— | — |
| SCYNEXIS, Inc.NasdaqCM: SCYX | $50.94M | $4.22 | -17.58% |
| May & Baker Nigeria plcNGSE: MAYBAKER | $50.92M | ₦39.20 | -5.08% |
Figures last refreshed Oct 4, 2026.